INFORMATION DISCLOSURE CITATION	Docket No.: RLL-283US	Serial No.: 10/540,062
	Applicants: [redacted]TA *et al.*	
	Filed: 6/22/2005	Group: 1625

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
YD	A1	3,176,019	3/30/1965	Campbell *et al.*	260	293.4	
	A2	5,281,601	1/25/1994	Cross *et al.*	514	320	
	A3	5,948,792	9/7/1999	Tsuchiya *et al.*	514	317	
	A4	6,130,232	10/10/2000	Mase *et al.*	514	318	
	A5	6,174,900	1/16/2001	Okada *et al.*	514	317	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES | NO
YD	B1	EP 0 072 620	2/23/1983	EPO	C07D	405/12	|
	B2	EP 0 108 986	5/23/1984	EPO	C07D	311/30	|
	B3	EP 0 267 319	5/18/1988	EPO	C07C	153/11	|
	B4	EP 0 325 571	7/26/1989	EPO	C07C	215/54	|
	B5	EP 0 388 054	9/19/1990	EPO	C07D	207/08	|
	B6	EP 0 801 067	10/15/1997	EPO	C07D	453/02	|
	B7	GB 940,540	10/30/1963	UK	C07C		|
	B8	JP 135958/1994	5/17/1994	Japan	C07D	333/16	|
	B9	JP 92921/1994	4/5/1994	Japan	C07C	237/20	|
	B10	WO 91/09013	6/27/1991	PCT	C07D	207/08	|
	B11	WO 93/16018	8/19/1993	PCT	C05F	17/02	|
	B12	WO 93/16048	8/19/1993	PCT	C07D	211/26	Equivalent CA 2155320
	B13	WO 96/33973	10/31/1996	PCT	C07D	211/46	Equivalent US 5,750,540
	B14	WO 97/45414	12/4/1997	PCT	C07D	211/58	Abstract
	B15	WO 98/05641	2/12/1998	PCT	C07D	211/46	Equivalent US 5,948,792
	B16	WO 98/29402	7/9/1998	PCT	C07D	311/20	|
							|

EXAMINER	T. A. Solola	DATE CONSIDERED	9-11-07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-283US	Serial No.: 10/540,062
	Applicants: [redacted]TA *et al.*	
	Filed: 6/22/2005	Group: 1625

		OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)
Yb	C1	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", *Nature*, 323(2):411-416 (1986)
	C2	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", *Science*, 237:527-531 (1987)
	C3	Eglen et al., "Muscarinic receptor ligands and their theraputic potential", *Current Opinion in Chemical Biology*, 3:426-432 (1999)
	C4	Eglen et al., "Theraputic opportunities from muscarinic receptor research", *Trends in Pharmacological Sciences*, 22(8):409-414 (2001)
	C5	Felder et al., "Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System", *Journal of Medicinal Chemistry*, 43(23):4333-4353 (2000)
	C6	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", *Molecules*, 6:142-193 (2001)
	C7	Birdsall et al., "Muscarinic receptors: it's a knockout", *Trends in Pharmacological Sciences*, 22(5):215-219 (2001)
	C8	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", *Annual Review of Pharmacology and Toxicology*, 41:691-721 (2001)
	C9	Steers, "The future direction of neuro-urology drug research", *Current Opinion in CPNS Investigational Drugs*, 2(3):268-282
	C10	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", *Urology*, 55(Suppl. 5A):33-46 (2000)
	C11	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: *Adult and Pediatric Urology*, ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)
	C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M_3 Antagonist Discriminating against the Other Receptor Subtypes", *Journal of Medicinal Chemistry*, 45:984-987 (2002)
	C13	Braish et al., "Construction of the (1α,5α,6α)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", *Synlett*, 1100-1102 (1996)
	C14	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", *Life Sciences*, 64(25):2351-2358 (1999)
	C15	Cheng and Prusoff, "Relationship between the inhibition constant (K_1) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction", *Biochemical Pharmacology*, 22:3099-3108 (1973)

EXAMINER	T. A. Solola	DATE CONSIDERED	9-11-07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.